

Springer Nature is making Coronavirus research free. [View research](#) | [View latest news](#) | [Sign up for updates](#)

# Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative

American Journal of Clinical Dermatology

pp 1–16 | Cite as

- Lourdes M. Perez-Chada (1) [View author's OrcID profile](#) ([View OrcID profile](#))
- Nicole F. Salame (2)
- Adam R. Ford (3)
- Kristina Callis Duffin (4)
- Amit Garg (5)
- Alice B. Gottlieb (6)
- John Latella (7)
- Joseph F. Merola (1) (8)
- April W. Armstrong (9) [Email author](mailto:armstrongpublication@gmail.com) ([armstrongpublication@gmail.com](mailto:armstrongpublication@gmail.com))

1. Department of Dermatology, Brigham and Women's Hospital, , Boston, USA
2. Irvine School of Medicine, University of California, , Irvine, USA
3. Keck School of Medicine of the University of Southern California, , Los Angeles, USA
4. Department of Dermatology, University of Utah, , Salt Lake City, USA
5. Department of Dermatology, Hofstra Northwell School of Medicine, , New Hyde Park, USA
6. Department of Dermatology, Icahn School of Medicine at Mount Sinai, , New York, USA
7. International Dermatology Outcome Measures (IDEOM), , Windsor, USA
8. Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, , Boston, USA
9. Department of Dermatology, Keck School of Medicine of the University of Southern California, , Los Angeles, USA

Systematic Review

First Online: 16 January 2020

- [1 Shares](#)

# Abstract

## Background and Objective

The International Dermatology Outcome Measures (IDEOM) has defined a core set of domains to be measured in all psoriasis clinical trials. This set comprises the following domains: skin manifestations, psoriasis and psoriatic arthritis symptoms, health-related quality of life, investigator global, patient global, and treatment satisfaction. The next step is to define how to measure these domains. The objective of this article was to evaluate the quality of available instruments to assess ‘investigator global’ and ‘patient global’ domains to identify the most appropriate instruments.

## Methods

Reviewers conducted a systematic literature review to retrieve studies on the measurement properties of instruments including either an investigator global assessment or a patient global assessment. Following the CONsensus based standards for the Selection of health Measurement INstruments (COSMIN) checklist, three independent reviewers rated the quality of each study. We then performed a qualitative synthesis of the evidence.

## Results

We identified nine investigator global assessments and three patient global assessments, reflecting substantial variability in global assessment instruments. Overall, most measures lacked evidence for content validity and feasibility. The Lattice System-Physician Global Assessment, Product of the Investigator Global Assessment and Body Surface Area, and the professional-Simplified Psoriasis Index had higher levels of evidence for validity, reliability, and/or responsiveness than the 5- and 6-point investigator global assessments. The self-assessment-Simplified Psoriasis Index was the only patient global assessment with evidence for validity, reliability, and responsiveness.

## Conclusions

The 5- and 6-point investigator global assessments, which are the most widely used investigator global assessments in registered clinical trials, have less evidence for measurement properties as compared with the Lattice System-Physician Global Assessment, professional-Simplified Psoriasis Index, and the Product of the Investigator Global Assessment and Body Surface Area. However, all instruments lack evidence for

content validity and feasibility. Further validation studies of investigator global assessments and patient global assessments are required to recommend the best global measure for psoriasis clinical trials.

L. M. Perez-Chada and N. F. Salame are co-primary authors.

## Electronic supplementary material

The online version of this article (<https://doi.org/10.1007/s40257-019-00496-w> (<https://doi.org/10.1007/s40257-019-00496-w>)) contains supplementary material, which is available to authorized users.

This is a preview of subscription content, [log in](#) to check access.

## Notes

### Compliance with Ethical Standards

### Funding

International Dermatology Outcome Measures (IDEOM) funded the conduct of this study.

### Conflict of interest

Dr. Garg is a consultant/advisor for Abbvie, Pfizer, UCB, and Asana Biosciences and received a grant from UCB. Dr. Gottlieb is an advisor/consultant for Janssen Inc., Celgene, Beiersdorf, BMS, Abbvie, UCB, Novartis, Incyte Corporation, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries, XBiotech, Leo, Avotres Therapeutics, and Boeringer Ingelheim. She received research/educational grants from Janssen, Incyte Corporation, XBiotech, Novartis, Boeringer Ingelheim, and UCB. In addition, she participated in the development of the National Psoriasis Foundation Psoriasis Score, an instrument discussed in the present study. John Latella is an advisor for Boehringer Ingelheim and Glaxo Smith Kline. Dr. Duffin serves as an advisory board/consultant/investigator for Amgen, Abbvie, Celgene, Novartis, Lilly, Pfizer, Stifle, Janssen, Ortho Dermatologic, and Boehringer Ingelheim. In addition, she has participated in validation studies of the IGA×BSA, an instrument discussed in the present study. Dr. Merola has served as a consultant/investigator/advisory board for Merck, AbbVie Eli Lilly, Incyte, Janssen, UCB, Almirall, Pfizer, Sun Pharma, Novartis, and Burrage Capital Mgmt. In addition, he received grants from Aclaris, Novartis, Leo, Celgene, and Dermavent. Dr. Armstrong serves as a consultant/advisor/investigator for Leo Pharma, Novartis, Delmira, UCB, Abbvie, Janssen, Eli Lilly, Regeneron and Sanofi,

Science 37, Modernizing Medicine, Merck, Parexel, Celgene, Ortho Dermatologics, and Pfizer. Drs. Perez-Chada, Salame, and Ford have no conflicts of interest that are directly relevant to the content of this article.

## Supplementary material

[40257\\_2019\\_496\\_MOESM1\\_ESM.pdf](#) (632 kb)

Supplementary file1 (PDF 632 kb)

## References

- Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST et al. The COMET Handbook: version 1.0. *Trials*. 2017;18(Suppl 3):280. 10.1186/s13063-017-1978-4.  
[Google Scholar](https://scholar.google.com/scholar?q=Williamson%20PR%2C%20Altman%20DG%2C%20Bagley%20H%2C%20Barnes%20KL%2C%20Blazeby%20JM%2C%20Brookes%20ST%20et%20al.%20The%20COMET%20Handbook%3A%20version%201.0.%20Trials.%202017%3B18%28Suppl%203%29%3A280.%2010.1186%2Fs13063-017-1978-4.) (<https://scholar.google.com/scholar?q=Williamson%20PR%2C%20Altman%20DG%2C%20Bagley%20H%2C%20Barnes%20KL%2C%20Blazeby%20JM%2C%20Brookes%20ST%20et%20al.%20The%20COMET%20Handbook%3A%20version%201.0.%20Trials.%202017%3B18%28Suppl%203%29%3A280.%2010.1186%2Fs13063-017-1978-4.>)
- Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, et al. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. *J Am Acad Dermatol*. 2015;72(2):345–8. <https://doi.org/10.1016/j.jaad.2014.11.002> (<https://doi.org/10.1016/j.jaad.2014.11.002>).  
[CrossRef](https://doi.org/10.1016/j.jaad.2014.11.002) (<https://doi.org/10.1016/j.jaad.2014.11.002>)  
[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25486914) ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=25486914](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25486914))  
[Google Scholar](http://scholar.google.com/scholar_lookup?title=The%20International%20Dermatology%20Outcome%20Measures%20Group%3A%20formation%20of%20patient-centered%20outcome%20measures%20in%20dermatology&author=AB.%20Gottlieb&author=AA.%20Levin&author=AW.%20Armstrong&author=A.%20Abernethy&author=KC.%20Duffin&author=R.%20Bhushan&journal=J%20Am%20Acad%20Dermatol&volume=72&issue=2&pages=345-348&publication_year=2015&doi=10.1016%2Fj.jaad.2014.11.002) ([http://scholar.google.com/scholar\\_lookup?title=The%20International%20Dermatology%20Outcome%20Measures%20Group%3A%20formation%20of%20patient-centered%20outcome%20measures%20in%20dermatology&author=AB.%20Gottlieb&author=AA.%20Levin&author=AW.%20Armstrong&author=A.%20Abernethy&author=KC.%20Duffin&author=R.%20Bhushan&journal=J%20Am%20Acad%20Dermatol&volume=72&issue=2&pages=345-348&publication\\_year=2015&doi=10.1016%2Fj.jaad.2014.11.002](http://scholar.google.com/scholar_lookup?title=The%20International%20Dermatology%20Outcome%20Measures%20Group%3A%20formation%20of%20patient-centered%20outcome%20measures%20in%20dermatology&author=AB.%20Gottlieb&author=AA.%20Levin&author=AW.%20Armstrong&author=A.%20Abernethy&author=KC.%20Duffin&author=R.%20Bhushan&journal=J%20Am%20Acad%20Dermatol&volume=72&issue=2&pages=345-348&publication_year=2015&doi=10.1016%2Fj.jaad.2014.11.002))
- Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. *J Rheumatol*. 1998;25(2):198–9.  
[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9489805) ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=9489805](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9489805))  
[Google Scholar](http://scholar.google.com/scholar_lookup?title=The%20OMERACT%20filter%20for%20outcome%20measures%20in%20rheumatology&author=M.%20Boers&author=P.%20Brooks&author=CV.%20Strand&author=P.%20Tugwell&journal=J%20Rheumatol.&volume=25&issue=2&pages=198-199&publication_year=1998) ([http://scholar.google.com/scholar\\_lookup?title=The%20OMERACT%20filter%20for%20outcome%20measures%20in%20rheumatology&author=M.%20Boers&author=P.%20Brooks&author=CV.%20Strand&author=P.%20Tugwell&journal=J%20Rheumatol.&volume=25&issue=2&pages=198-199&publication\\_year=1998](http://scholar.google.com/scholar_lookup?title=The%20OMERACT%20filter%20for%20outcome%20measures%20in%20rheumatology&author=M.%20Boers&author=P.%20Brooks&author=CV.%20Strand&author=P.%20Tugwell&journal=J%20Rheumatol.&volume=25&issue=2&pages=198-199&publication_year=1998))
- Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, et al. Identifying a core domain set to assess psoriasis in clinical trials. *JAMA Dermatol*.

2018. <https://doi.org/10.1001/jamadermatol.2018.1165>

(<https://doi.org/10.1001/jamadermatol.2018.1165>).

**CrossRef** (<https://doi.org/10.1001/jamadermatol.2018.1165>)

**PubMed** (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?>

[cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=29874367](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29874367))

**PubMedCentral** (<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233740>)

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)

[title=Identifying%20a%20core%20domain%20set%20to%20assess%20psoriasis%20in%20clinical%20trials&author=K.%20Callis%20Duffin&author=JF.%20Merola&author=R.%20Christensen&author=J.%20Latella&author=A.%20Garg&author=AB.%20Gottlieb&journal=JAMA%20Dermatol.&publication\\_year=2018&doi=10.1001%2Fjamadermatol.2018.1165](http://scholar.google.com/scholar_lookup?title=Identifying%20a%20core%20domain%20set%20to%20assess%20psoriasis%20in%20clinical%20trials&author=K.%20Callis%20Duffin&author=JF.%20Merola&author=R.%20Christensen&author=J.%20Latella&author=A.%20Garg&author=AB.%20Gottlieb&journal=JAMA%20Dermatol.&publication_year=2018&doi=10.1001%2Fjamadermatol.2018.1165))

5. Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set”—a practical guideline. *Trials*. 2016;17(1):449.  
**CrossRef** (<https://doi.org/10.1186/s13063-016-1555-2>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)  
[title=How%20to%20select%20outcome%20measurement%20instruments%20for%20outcomes%20included%20in%20a%20%E2%80%9CCore%20Outcome%20Set%E2%80%9D%E2%80%94a%20practical%20guideline&author=CA.%20Prinsen&author=S.%20Vohra&author=MR.%20Rose&author=M.%20Boers&author=P.%20Tugwell&author=M.%20Clarke&journal=Trials.&volume=17&issue=1&pages=449&publication\\_year=2016](http://scholar.google.com/scholar_lookup?title=How%20to%20select%20outcome%20measurement%20instruments%20for%20outcomes%20included%20in%20a%20%E2%80%9CCore%20Outcome%20Set%E2%80%9D%E2%80%94a%20practical%20guideline&author=CA.%20Prinsen&author=S.%20Vohra&author=MR.%20Rose&author=M.%20Boers&author=P.%20Tugwell&author=M.%20Clarke&journal=Trials.&volume=17&issue=1&pages=449&publication_year=2016))
6. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. 2009;6(7):e1000100.  
**CrossRef** (<https://doi.org/10.1371/journal.pmed.1000100>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)  
[title=The%20PRISMA%20statement%20for%20reporting%20systematic%20reviews%20and%20meta-analyses%20of%20studies%20that%20evaluate%20health%20care%20interventions%3A%20explanation%20and%20elaboration&author=A.%20Liberati&author=DG.%20Altman&author=J.%20Tetzlaff&author=C.%20Mulrow&author=PC.%20G%C3%B8tzsche&author=JP.%20Ioannidis&journal=PLoS%20Med.&volume=6&issue=7&pages=e1000100&publication\\_year=2009](http://scholar.google.com/scholar_lookup?title=The%20PRISMA%20statement%20for%20reporting%20systematic%20reviews%20and%20meta-analyses%20of%20studies%20that%20evaluate%20health%20care%20interventions%3A%20explanation%20and%20elaboration&author=A.%20Liberati&author=DG.%20Altman&author=J.%20Tetzlaff&author=C.%20Mulrow&author=PC.%20G%C3%B8tzsche&author=JP.%20Ioannidis&journal=PLoS%20Med.&volume=6&issue=7&pages=e1000100&publication_year=2009))
7. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. *J Dermatol Treat*. 2015;26(1):23–31.  
<https://doi.org/10.3109/09546634.2013.865009>  
(<https://doi.org/10.3109/09546634.2013.865009>).  
**CrossRef** (<https://doi.org/10.3109/09546634.2013.865009>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)  
[title=The%205-point%20Investigator%27s%20Global%20Assessment%20%28IGA%29%20Scale%3A%20A%20modified%20tool%20for%20evaluating%20plaque%20psoriasis%20severity%20in%20clinical%20trials&author=RG.%20Langley&author=SR.%20Feldman&author=J.%20Nyirady&author=P.%20Kerkhof&author=C.%20Papavassilis&journal=J%20Dermatol%20Treat.&volume=26&issue=1&pages=23-31&publication\\_year=2015&doi=10.3109%2F09546634.2013.865009](http://scholar.google.com/scholar_lookup?title=The%205-point%20Investigator%27s%20Global%20Assessment%20%28IGA%29%20Scale%3A%20A%20modified%20tool%20for%20evaluating%20plaque%20psoriasis%20severity%20in%20clinical%20trials&author=RG.%20Langley&author=SR.%20Feldman&author=J.%20Nyirady&author=P.%20Kerkhof&author=C.%20Papavassilis&journal=J%20Dermatol%20Treat.&volume=26&issue=1&pages=23-31&publication_year=2015&doi=10.3109%2F09546634.2013.865009))

8. Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. *JDD*. 2017;16(2):147–53.  
PubMed ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=28300857](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28300857))  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=Evaluation%20of%20the%20physician%20global%20assessment%20and%20body%20surface%20area%20composite%20tool%20for%20assessing%20psoriasis%20response%20to%20apremilast%20therapy%3A%20results%20from%20ESTEEM%201%20and%20ESTEEM%202&author=KC.%20Duffin&author=KA.%20Papp&author=J.%20Bagel&author=E.%20Levi&author=R.%20Chen&author=AB.%20Gottlieb&journal=JDD.&volume=16&issue=2&pages=147-153&publication\\_year=2017](http://scholar.google.com/scholar_lookup?title=Evaluation%20of%20the%20physician%20global%20assessment%20and%20body%20surface%20area%20composite%20tool%20for%20assessing%20psoriasis%20response%20to%20apremilast%20therapy%3A%20results%20from%20ESTEEM%201%20and%20ESTEEM%202&author=KC.%20Duffin&author=KA.%20Papp&author=J.%20Bagel&author=E.%20Levi&author=R.%20Chen&author=AB.%20Gottlieb&journal=JDD.&volume=16&issue=2&pages=147-153&publication_year=2017))
  
9. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. *J Am Acad Dermatol*. 2004;51(4):563–9.  
<https://doi.org/10.1016/j.jaad.2004.04.012>  
 (<https://doi.org/10.1016/j.jaad.2004.04.012>).  
CrossRef (<https://doi.org/10.1016/j.jaad.2004.04.012>)  
PubMed ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=15389191](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15389191))  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=Evaluating%20psoriasis%20with%20psoriasis%20area%20and%20severity%20index%2C%20psoriasis%20global%20assessment%2C%20and%20lattice%20system%20physician%27s%20global%20assessment&author=RG.%20Langley&author=CN.%20Ellis&journal=J%20Am%20Acad%20Dermatol&volume=51&issue=4&pages=563-569&publication\\_year=2004&doi=10.1016%2Fj.jaad.2004.04.012](http://scholar.google.com/scholar_lookup?title=Evaluating%20psoriasis%20with%20psoriasis%20area%20and%20severity%20index%2C%20psoriasis%20global%20assessment%2C%20and%20lattice%20system%20physician%27s%20global%20assessment&author=RG.%20Langley&author=CN.%20Ellis&journal=J%20Am%20Acad%20Dermatol&volume=51&issue=4&pages=563-569&publication_year=2004&doi=10.1016%2Fj.jaad.2004.04.012))
  
10. Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. *Arthritis Res Ther*. 2016;18(1):251.  
<https://doi.org/10.1186/s13075-016-1151-6> (<https://doi.org/10.1186/s13075-016-1151-6>).  
CrossRef (<https://doi.org/10.1186/s13075-016-1151-6>)  
PubMed ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=27793211](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27793211))  
PubMedCentral (<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086038>)  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=Patient%20global%20assessment%20in%20measuring%20disease%20activity%20in%20rheumatoid%20arthritis%3A%20a%20review%20of%20the%20literature&author=E.%20Nikiphorou&author=H.%20Radner&author=K.%20Chatzidionysiou&author=C.%20Desthieux&author=C.%20Zabalan&author=Y.%20Eijk-Hustings&journal=Arthritis%20Res%20Ther.&volume=18&issue=1&pages=251&publication\\_year=2016&doi=10.1186%2Fs13075-016-1151-6](http://scholar.google.com/scholar_lookup?title=Patient%20global%20assessment%20in%20measuring%20disease%20activity%20in%20rheumatoid%20arthritis%3A%20a%20review%20of%20the%20literature&author=E.%20Nikiphorou&author=H.%20Radner&author=K.%20Chatzidionysiou&author=C.%20Desthieux&author=C.%20Zabalan&author=Y.%20Eijk-Hustings&journal=Arthritis%20Res%20Ther.&volume=18&issue=1&pages=251&publication_year=2016&doi=10.1186%2Fs13075-016-1151-6))
  
11. Talli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Canete JD, et al. Patient global assessment in psoriatic arthritis—what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. *Joint Bone Spine Revue du rhumatisme*. 2016;83(3):335–40.

<https://doi.org/10.1016/j.jbspin.2015.06.018>

(<https://doi.org/10.1016/j.jbspin.2015.06.018>).

**CrossRef** (<https://doi.org/10.1016/j.jbspin.2015.06.018>)

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)

title=Patient%20global%20assessment%20in%20psoriatic%20arthritis%E2%80%94%94what%20does%20it%20mean%3F%20An%20analysis%20of%20223%20patients%20from%20the%20psoriatic%20arthritis%20impact%20of%20disease%20%28PsAID%29%20study&author=S.%20Talli&author=A.%20Etcheto&author=B.%20Fautrel&author=A.%20Balanescu&author=J.%20Braun&author=JD.%20Canete&journal=Joint%20Bone%20Spine%20Revue%20du%20rhumatisme.&volume=83&issue=3&pages=335-340&publication\_year=2016&doi=10.1016%2Fj.jbspin.2015.06.018)

12. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. *BMC Med Res Methodol.* 2010;10:22. <https://doi.org/10.1186/1471-2288-10-22>

(<https://doi.org/10.1186/1471-2288-10-22>).

**CrossRef** (<https://doi.org/10.1186/1471-2288-10-22>)

**PubMed** (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?>

cmd=Retrieve&db=PubMed&dopt=Abstract&list\_uids=20298572)

**PubMedCentral** (<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848183>)

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)

title=The%20COSMIN%20checklist%20for%20evaluating%20the%20methodological%20quality%20of%20studies%20on%20measurement%20properties%3A%20a%20clarification%20of%20its%20content&author=LB.%20Mokkink&author=CB.%20Terwee&author=DL.%20Knol&author=PW.%20Stratford&author=J.%20Alonso&author=DL.%20Patrick&journal=BMC%20Med%20Res%20Methodol&volume=10&pages=22&publication\_year=2010&doi=10.1186%2F1471-2288-10-22)

13. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. *Qual Life Res.* 2012;21(4):651–7. <https://doi.org/10.1007/s11136-011-9960-1>

(<https://doi.org/10.1007/s11136-011-9960-1>).

**CrossRef** (<https://doi.org/10.1007/s11136-011-9960-1>)

**PubMed** (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?>

cmd=Retrieve&db=PubMed&dopt=Abstract&list\_uids=21732199)

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?](http://scholar.google.com/scholar_lookup?)

title=Rating%20the%20methodological%20quality%20in%20systematic%20reviews%20of%20studies%20on%20measurement%20properties%3A%20a%20scoring%20system%20for%20the%20COSMIN%20checklist&author=CB.%20Terwee&author=LB.%20Mokkink&author=DL.%20Knol&author=RW.%20Ostelo&author=LM.%20Bouter&author=HC.%20Vet&journal=Qual%20Life%20Res.&volume=21&issue=4&pages=651-657&publication\_year=2012&doi=10.1007%2Fs11136-011-9960-1)

14. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol.* 2007;60:34–42.

**CrossRef** (<https://doi.org/10.1016/j.jclinepi.2006.03.012>)

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Quality%20criteria%20were%20proposed%20for%20measurement%20properties%20of%20health%20status%20questionnaires&author=CB.%20Terwee&author=SD.%20Bot&author=MR.%20Boer&author=DA.%20Windt&author=DL.%20Knol&author=J.%20Dekker&journal=J%20Clin%20Epidemiol.&volume=60&pages=34-42&publication\\_year=2007](http://scholar.google.com/scholar_lookup?title=Quality%20criteria%20were%20proposed%20for%20measurement%20properties%20of%20health%20status%20questionnaires&author=CB.%20Terwee&author=SD.%20Bot&author=MR.%20Boer&author=DA.%20Windt&author=DL.%20Knol&author=J.%20Dekker&journal=J%20Clin%20Epidemiol.&volume=60&pages=34-42&publication_year=2007))

15. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine*. 2009;34(18):1929–41. <https://doi.org/10.1097/BRS.ob013e3181b1c99f> (<https://doi.org/10.1097/BRS.ob013e3181b1c99f>).  
**CrossRef** (<https://doi.org/10.1097/BRS.ob013e3181b1c99f>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=19680101](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19680101))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=2009%20updated%20method%20guidelines%20for%20systematic%20reviews%20in%20the%20Cochrane%20Back%20Review%20Group&author=AD.%20Furlan&author=V.%20Pennick&author=C.%20Bombardier&author=M.%20Tulder&journal=Spine.&volume=34&issue=18&pages=1929-1941&publication\\_year=2009&doi=10.1097%2FBRS.ob013e3181b1c99f](http://scholar.google.com/scholar_lookup?title=2009%20updated%20method%20guidelines%20for%20systematic%20reviews%20in%20the%20Cochrane%20Back%20Review%20Group&author=AD.%20Furlan&author=V.%20Pennick&author=C.%20Bombardier&author=M.%20Tulder&journal=Spine.&volume=34&issue=18&pages=1929-1941&publication_year=2009&doi=10.1097%2FBRS.ob013e3181b1c99f))
16. Fayers PM, Hand DJ, Bjordal K, Groenvold M. Causal indicators in quality of life research. *Qual Life Res*. 1997 Sep 1;6(5):393–406.  
**CrossRef** (<https://doi.org/10.1023/A%3A1018491512095>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Causal%20indicators%20in%20quality%20of%20life%20research&author=PM.%20Fayers&author=DJ.%20Hand&author=K.%20Bjordal&author=M.%20Groenvold&journal=Qual%20Life%20Res&volume=6&issue=5&pages=393-406&publication\\_year=1997](http://scholar.google.com/scholar_lookup?title=Causal%20indicators%20in%20quality%20of%20life%20research&author=PM.%20Fayers&author=DJ.%20Hand&author=K.%20Bjordal&author=M.%20Groenvold&journal=Qual%20Life%20Res&volume=6&issue=5&pages=393-406&publication_year=1997))
17. Prinsen CA, Mokkink LB, Bouter LM, Alonso J, Patrick DL, De Vet HC, Terwee CB. COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual Life Res*. 2018 May 1;27(5):1147–57.  
**CrossRef** (<https://doi.org/10.1007/s11136-018-1798-3>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=COSMIN%20guideline%20for%20systematic%20reviews%20of%20patient-reported%20outcome%20measures&author=CA.%20Prinsen&author=LB.%20Mokkink&author=LM.%20Bouter&author=J.%20Alonso&author=DL.%20Patrick&author=HC.%20Vet&author=CB.%20Terwee&journal=Qual%20Life%20Res&volume=27&issue=5&pages=1147-1157&publication\\_year=2018](http://scholar.google.com/scholar_lookup?title=COSMIN%20guideline%20for%20systematic%20reviews%20of%20patient-reported%20outcome%20measures&author=CA.%20Prinsen&author=LB.%20Mokkink&author=LM.%20Bouter&author=J.%20Alonso&author=DL.%20Patrick&author=HC.%20Vet&author=CB.%20Terwee&journal=Qual%20Life%20Res&volume=27&issue=5&pages=1147-1157&publication_year=2018))
18. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. *Br J Dermatol*. 2006;155(4):707–13. <https://doi.org/10.1111/j.1365-2133.2006.07389.x> (<https://doi.org/10.1111/j.1365-2133.2006.07389.x>).  
**CrossRef** (<https://doi.org/10.1111/j.1365-2133.2006.07389.x>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=16965419](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16965419))  
**Google Scholar** ([<https://link.springer.com/article/10.1007%2Fs40257-019-00496-w>](http://scholar.google.com/scholar_lookup?title=A%20study%20examining%20inter-</a></li>
</ol>
</div>
<div data-bbox=)



%20and%20intrarater%20reliability%20of%20three%20scales%20for%20measuring%20severity%20of%20psoriasis%3A%20Psoriasis%20Area%20and%20Severity%20Index%2C%20Physician%27s%20Global%20Assessment%20and%20Lattice%20System%20Physician%27s%20Global%20Assessment&author=J.%20Berth-Jones&author=K.%20Grotzinger&author=C.%20Rainville&author=B.%20Pham&author=J.%20Huang&author=S.%20Daly&journal=Br%20J%20Dermatol.&volume=155&issue=4&pages=707-713&publication\_year=2006&doi=10.1111%2Fj.1365-2133.2006.07389.x)

19. Simpson MJ, Chow C, Morgenstern H, Luger TA, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment. *JEADV*. 2015;29(7):1415–20. <https://doi.org/10.1111/jdv.12861> (<https://doi.org/10.1111/jdv.12861>).  
**CrossRef** (<https://doi.org/10.1111/jdv.12861>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=25917214](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25917214))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Comparison%20of%20three%20methods%20for%20measuring%20psoriasis%20severity%20in%20clinical%20studies%20%28Part%202%20of%202%29%3A%20use%20of%20quality%20of%20life%20to%20assess%20construct%20validity%20of%20the%20Lattice%20System%20Physician%27s%20Global%20Assessment%2C%20Psoriasis%20Area%20and%20Severity%20Index%20and%20Static%20Physician%27s%20Global%20Assessment&author=MJ.%20Simpson&author=C.%20Chow&author=H.%20Morgenstern&author=TA.%20Luger&author=CN.%20Ellis&journal=JEADV.&volume=29&issue=7&pages=1415-1420&publication\\_year=2015&doi=10.1111%2Fjdv.12861](http://scholar.google.com/scholar_lookup?title=Comparison%20of%20three%20methods%20for%20measuring%20psoriasis%20severity%20in%20clinical%20studies%20%28Part%202%20of%202%29%3A%20use%20of%20quality%20of%20life%20to%20assess%20construct%20validity%20of%20the%20Lattice%20System%20Physician%27s%20Global%20Assessment%2C%20Psoriasis%20Area%20and%20Severity%20Index%20and%20Static%20Physician%27s%20Global%20Assessment&author=MJ.%20Simpson&author=C.%20Chow&author=H.%20Morgenstern&author=TA.%20Luger&author=CN.%20Ellis&journal=JEADV.&volume=29&issue=7&pages=1415-1420&publication_year=2015&doi=10.1111%2Fjdv.12861))
20. Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. *JEADV*. 2015;29(7):1406–14. <https://doi.org/10.1111/jdv.13132> (<https://doi.org/10.1111/jdv.13132>).  
**CrossRef** (<https://doi.org/10.1111/jdv.13132>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=25917315](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25917315))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Comparison%20of%20three%20methods%20for%20measuring%20psoriasis%20severity%20in%20clinical%20studies%20%28Part%201%20of%202%29%3A%20change%20during%20therapy%20in%20Psoriasis%20Area%20and%20Severity%20Index%2C%20Static%20Physician%27s%20Global%20Assessment%20and%20Lattice%20System%20Physician%27s%20Global%20Assessment&author=C.%20Chow&author=MJ.%20Simpson&author=TA.%20Luger&author=H.%20Chubb&author=CN.%20Ellis&journal=JEADV.&volume=29&issue=7&pages=1406-1414&publication\\_year=2015&doi=10.1111%2Fjdv.13132](http://scholar.google.com/scholar_lookup?title=Comparison%20of%20three%20methods%20for%20measuring%20psoriasis%20severity%20in%20clinical%20studies%20%28Part%201%20of%202%29%3A%20change%20during%20therapy%20in%20Psoriasis%20Area%20and%20Severity%20Index%2C%20Static%20Physician%27s%20Global%20Assessment%20and%20Lattice%20System%20Physician%27s%20Global%20Assessment&author=C.%20Chow&author=MJ.%20Simpson&author=TA.%20Luger&author=H.%20Chubb&author=CN.%20Ellis&journal=JEADV.&volume=29&issue=7&pages=1406-1414&publication_year=2015&doi=10.1111%2Fjdv.13132))
21. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. *J Am Acad Dermatol*. 2013;69(6):931–7. <https://doi.org/10.1016/j.jaad.2013.07.040> (<https://doi.org/10.1016/j.jaad.2013.07.040>).

**CrossRef** (<https://doi.org/10.1016/j.jaad.2013.07.040>)

**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=24054760](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24054760))

**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Product%20of%20the%20Physician%20Global%20Assessment%20and%20body%20surface%20area%3A%20a%20simple%20static%20measure%20of%20psoriasis%20severity%20in%20a%20longitudinal%20cohort&author=JA.%20Wals%20h&author=M.%20McFadden&author=J.%20Woodcock&author=DO.%20Clegg&author=P.%20Helliwell&author=E.%20Dommasch&journal=J%20Am%20Acad%20Dermatol&volume=69&issue=6&pages=931-937&publication\\_year=2013&doi=10.1016%2Fj.jaad.2013.07.040](http://scholar.google.com/scholar_lookup?title=Product%20of%20the%20Physician%20Global%20Assessment%20and%20body%20surface%20area%3A%20a%20simple%20static%20measure%20of%20psoriasis%20severity%20in%20a%20longitudinal%20cohort&author=JA.%20Wals%20h&author=M.%20McFadden&author=J.%20Woodcock&author=DO.%20Clegg&author=P.%20Helliwell&author=E.%20Dommasch&journal=J%20Am%20Acad%20Dermatol&volume=69&issue=6&pages=931-937&publication_year=2013&doi=10.1016%2Fj.jaad.2013.07.040))

22. Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, et al. Evaluation of sPGA x BSA as an outcome measure and treatment target for clinical practice. *J Invest Dermatol.* 2018. <https://doi.org/10.1016/j.jid.2018.01.041> (<https://doi.org/10.1016/j.jid.2018.01.041>).  
**CrossRef** (<https://doi.org/10.1016/j.jid.2018.01.041>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=30243657](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30243657))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Evaluation%20of%20sPGA%20x%20BSA%20as%20an%20outcome%20measure%20and%20treatment%20target%20for%20clinical%20practice&author=JF.%20Merola&author=DA.%20Amato&author=K.%20See&author=R.%20Burge&author=C.%20Mallinckrodt&author=CK.%20Ojeh&journal=J%20Invest%20Dermatol&publication\\_year=2018&doi=10.1016%2Fj.jid.2018.01.041](http://scholar.google.com/scholar_lookup?title=Evaluation%20of%20sPGA%20x%20BSA%20as%20an%20outcome%20measure%20and%20treatment%20target%20for%20clinical%20practice&author=JF.%20Merola&author=DA.%20Amato&author=K.%20See&author=R.%20Burge&author=C.%20Mallinckrodt&author=CK.%20Ojeh&journal=J%20Invest%20Dermatol&publication_year=2018&doi=10.1016%2Fj.jid.2018.01.041))
23. Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. *J Invest Dermatol.* 2013;133(8):1956–62. <https://doi.org/10.1038/jid.2013.138> (<https://doi.org/10.1038/jid.2013.138>).  
**CrossRef** (<https://doi.org/10.1038/jid.2013.138>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=23807685](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23807685))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=The%20Simplified%20Psoriasis%20Index%20%28SPI%29%3A%20a%20practical%20tool%20for%20assessing%20psoriasis&author=L.%20Chularojanamontri&author=CE.%20Griffiths&author=RJ.%20Chalmers&journal=J%20Invest%20Dermatol&volume=133&issue=8&pages=1956-1962&publication\\_year=2013&doi=10.1038%2Fjid.2013.138](http://scholar.google.com/scholar_lookup?title=The%20Simplified%20Psoriasis%20Index%20%28SPI%29%3A%20a%20practical%20tool%20for%20assessing%20psoriasis&author=L.%20Chularojanamontri&author=CE.%20Griffiths&author=RJ.%20Chalmers&journal=J%20Invest%20Dermatol&volume=133&issue=8&pages=1956-1962&publication_year=2013&doi=10.1038%2Fjid.2013.138))
24. Meah N, Alsharqi A, Azurdia RM, Owens LC, Parslew R, Chularojanamontri L. Assessing the validity and response distribution of the simplified psoriasis index in patients receiving phototherapy. *Aust J Dermatol.* 2018;59(1):41–7. <https://doi.org/10.1111/ajd.12549> (<https://doi.org/10.1111/ajd.12549>).  
**CrossRef** (<https://doi.org/10.1111/ajd.12549>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Assessing%20the%20validity%20and%20response%20distribution%20of%20the%20simplified%20psoriasis%20index%20in%20patients%20receiving%20phototherapy&author=N.%20Meah&author=A.%20Alsharqi&author=RM.%20Azurdia&author=LC.%20Owens&author=R.%20Parslew&author=L.%20Chularojanamontri&journal=Aust%20J%20Dermatol.&volume=59&issue=1&pages=41-47&publication\\_year=2018&doi=10.1111%2Fajd.12549](http://scholar.google.com/scholar_lookup?title=Assessing%20the%20validity%20and%20response%20distribution%20of%20the%20simplified%20psoriasis%20index%20in%20patients%20receiving%20phototherapy&author=N.%20Meah&author=A.%20Alsharqi&author=RM.%20Azurdia&author=LC.%20Owens&author=R.%20Parslew&author=L.%20Chularojanamontri&journal=Aust%20J%20Dermatol.&volume=59&issue=1&pages=41-47&publication_year=2018&doi=10.1111%2Fajd.12549))

25. Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. *J Invest Dermatol.* 2014;134(2):351–8. <https://doi.org/10.1038/jid.2013.318> (<https://doi.org/10.1038/jid.2013.318>).  
**CrossRef** (<https://doi.org/10.1038/jid.2013.318>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=23897275](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23897275))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Responsiveness%20to%20change%20and%20interpretability%20of%20the%20simplified%20psoriasis%20index&author=L.%20Chularojanamontri&author=CEM.%20Griffiths&author=RJG.%20Chalmers&journal=J%20Invest%20Dermatol&volume=134&issue=2&pages=351-358&publication\\_year=2014&doi=10.1038%2Fjid.2013.318](http://scholar.google.com/scholar_lookup?title=Responsiveness%20to%20change%20and%20interpretability%20of%20the%20simplified%20psoriasis%20index&author=L.%20Chularojanamontri&author=CEM.%20Griffiths&author=RJG.%20Chalmers&journal=J%20Invest%20Dermatol&volume=134&issue=2&pages=351-358&publication_year=2014&doi=10.1038%2Fjid.2013.318))
26. Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. *Qual Life Res.* 2013;22(9):2489–99. <https://doi.org/10.1007/s11136-013-0384-y> (<https://doi.org/10.1007/s11136-013-0384-y>).  
**CrossRef** (<https://doi.org/10.1007/s11136-013-0384-y>)  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=23475691](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23475691))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Psychometric%20validation%20of%20the%20physician%20global%20assessment%20scale%20for%20assessing%20severity%20of%20psoriasis%20disease%20activity&author=JC.%20Cappelleri&author=AG.%20Bushmakin&author=J.%20Harness&author=C.%20Mamolo&journal=Qual%20Life%20Res.&volume=22&issue=9&pages=2489-2499&publication\\_year=2013&doi=10.1007%2Fs11136-013-0384-y](http://scholar.google.com/scholar_lookup?title=Psychometric%20validation%20of%20the%20physician%20global%20assessment%20scale%20for%20assessing%20severity%20of%20psoriasis%20disease%20activity&author=JC.%20Cappelleri&author=AG.%20Bushmakin&author=J.%20Harness&author=C.%20Mamolo&journal=Qual%20Life%20Res.&volume=22&issue=9&pages=2489-2499&publication_year=2013&doi=10.1007%2Fs11136-013-0384-y))
27. Cohen AD, Van-Dijk D, Naggan L, Vardy DA. Factor analysis of the Beer Sheva Psoriasis Severity Score (BPSS). *IMAJ.* 2008;10(6):419–23.  
**PubMed** ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=18669137](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18669137))  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Factor%20analysis%20of%20the%20Beer%20Sheva%20Psoriasis%20Severity%20Score%20%28BPSS%29&author=AD.%20Cohen&author=D.%20Van-Dijk&author=L.%20Naggan&author=DA.%20Vardy&journal=IMAJ.&volume=10&issue=6&pages=419-423&publication\\_year=2008](http://scholar.google.com/scholar_lookup?title=Factor%20analysis%20of%20the%20Beer%20Sheva%20Psoriasis%20Severity%20Score%20%28BPSS%29&author=AD.%20Cohen&author=D.%20Van-Dijk&author=L.%20Naggan&author=DA.%20Vardy&journal=IMAJ.&volume=10&issue=6&pages=419-423&publication_year=2008))
28. Cohen AD, Van-Dijk D, Naggan L, Vardy DA. Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: a community-oriented study introducing the 'Beer Sheva Psoriasis Severity Score'. *J Dermatol Treat.* 2005;16(5–6):308–13.  
<https://doi.org/10.1080/09546630500375841> (<https://doi.org/10.1080/09546630500375841>).  
**CrossRef** (<https://doi.org/10.1080/09546630500375841>)  
**Google Scholar** ([http://scholar.google.com/scholar\\_lookup?title=Effectiveness%20of%20climatotherapy%20at%20the%20Dead%20Sea%20for%20psoriasis%20vulgaris%3A%20a%20community-oriented%20study%20introducing%20the%20%27Beer%20Sheva%20Psoriasis%20Severity%20Score%27&author=AD.%20Cohen&author=D.%20Van-Dijk&author=L.%20Naggan&author=DA.%20Vardy&journal=J%20Dermatol%20](http://scholar.google.com/scholar_lookup?title=Effectiveness%20of%20climatotherapy%20at%20the%20Dead%20Sea%20for%20psoriasis%20vulgaris%3A%20a%20community-oriented%20study%20introducing%20the%20%27Beer%20Sheva%20Psoriasis%20Severity%20Score%27&author=AD.%20Cohen&author=D.%20Van-Dijk&author=L.%20Naggan&author=DA.%20Vardy&journal=J%20Dermatol%20))

Treat.&volume=16&issue=5%E2%80%936&pages=308-313&publication\_year=2005&doi=10.1080%2F09546630500375841)

29. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. *JDD*. 2003;2(3):260–6.  
PubMed ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=12848110](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12848110))  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=The%20National%20Psoriasis%20Foundation%20Psoriasis%20Score%20%28NPF-PS%29%20system%20versus%20the%20Psoriasis%20Area%20Severity%20Index%20%28PASI%29%20and%20Physician%27s%20Global%20Assessment%20%28PGA%29%3A%20a%20comparison&author=AB.%20Gottlieb&author=U.%20Chaudhari&author=DG.%20Baker&author=M.%20Perate&author=LT.%20Dooley&journal=JDD.&volume=2&issue=3&pages=260-266&publication\\_year=2003](http://scholar.google.com/scholar_lookup?title=The%20National%20Psoriasis%20Foundation%20Psoriasis%20Score%20%28NPF-PS%29%20system%20versus%20the%20Psoriasis%20Area%20Severity%20Index%20%28PASI%29%20and%20Physician%27s%20Global%20Assessment%20%28PGA%29%3A%20a%20comparison&author=AB.%20Gottlieb&author=U.%20Chaudhari&author=DG.%20Baker&author=M.%20Perate&author=LT.%20Dooley&journal=JDD.&volume=2&issue=3&pages=260-266&publication_year=2003))
30. Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. *Arch Dermatol*. 1997;133(11):1443–8.  
CrossRef (<https://doi.org/10.1001/archderm.1997.03890470121019>)  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=Reliability%20Testing%20of%20the%20Dermatology%20Index%20of%20Disease%20Severity%20%28DIDS%29&author=Holly%20B..%20Faust&journal=Archives%20of%20Dermatology&volume=133&issue=11&pages=1443&publication\\_year=1997](http://scholar.google.com/scholar_lookup?title=Reliability%20Testing%20of%20the%20Dermatology%20Index%20of%20Disease%20Severity%20%28DIDS%29&author=Holly%20B..%20Faust&journal=Archives%20of%20Dermatology&volume=133&issue=11&pages=1443&publication_year=1997))
31. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. *Value Health*. 2007;10(Suppl 2):S125–S137. <https://doi.org/10.1111/j.1524-4733.2007.00275.x> (<https://doi.org/10.1111/j.1524-4733.2007.00275.x>).  
CrossRef (<https://doi.org/10.1111/j.1524-4733.2007.00275.x>)  
PubMed ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=17995471](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17995471))  
Google Scholar ([http://scholar.google.com/scholar\\_lookup?title=Patient-reported%20outcomes%20to%20support%20medical%20product%20labeling%20claims%3A%20FDA%20perspective&author=DL.%20Patrick&author=LB.%20Burke&author=JH.%20Powers&author=JA.%20Scott&author=EP.%20Rock&author=S.%20Dawisha&journal=Value%20Health.&volume=10&issue=Suppl%202&pages=S125-S137&publication\\_year=2007&doi=10.1111%2Fj.1524-4733.2007.00275.x](http://scholar.google.com/scholar_lookup?title=Patient-reported%20outcomes%20to%20support%20medical%20product%20labeling%20claims%3A%20FDA%20perspective&author=DL.%20Patrick&author=LB.%20Burke&author=JH.%20Powers&author=JA.%20Scott&author=EP.%20Rock&author=S.%20Dawisha&journal=Value%20Health.&volume=10&issue=Suppl%202&pages=S125-S137&publication_year=2007&doi=10.1111%2Fj.1524-4733.2007.00275.x))
32. Tugwell P, Boers M, D'Agostino M-A, Beaton D, Boonen A, Bingham CO et al. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. *J Rheumatol*. 2014;jrheum. 131310.  
Google Scholar (<https://scholar.google.com/scholar?q=Tugwell%20P%2C%20Boers%20M%2C%20D%20E2%80%99Agostino%20M-A%2C%20Beaton%20D%2C%20Boonen%20A%2C%20Bingham%20CO%20et%20al.%20Updating%20the%20OMERACT%20filter%3A%20implications%20of%2>

ofilter%202.0%20to%20select%20outcome%20instruments%20through%20assessment%20of%20%E2%80%9Ctruth%E2%80%9D%3A%20content%2C%20face%2C%20and%20construct%20validity.%20J%20Rheumatol.%202014%3Ajrheum.%20131310.)

33. Callis Duffin K, Gottlieb AB. Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting. *J Rheumatol.* 2013;40(8):1423–4.  
<https://doi.org/10.3899/jrheum.130454>  
 (https://doi.org/10.3899/jrheum.130454).  
**CrossRef** (https://doi.org/10.3899/jrheum.130454)  
**PubMed** (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\_uids=23908537)  
**Google Scholar** (http://scholar.google.com/scholar\_lookup?title=Outcome%20measures%20for%20psoriasis%20severity%3A%20a%20report%20from%20the%20GRAPPA%202012%20annual%20meeting&author=K.%20Callis%20Duffin&author=AB.%20Gottlieb&journal=J%20Rheumatol.&volume=40&issue=8&pages=1423-1424&publication\_year=2013&doi=10.3899%2Fjrheum.130454)
34. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. *J Am Acad Dermatol.* 2012;66(3):369–75.  
<https://doi.org/10.1016/j.jaad.2011.01.022>  
 (https://doi.org/10.1016/j.jaad.2011.01.022).  
**CrossRef** (https://doi.org/10.1016/j.jaad.2011.01.022)  
**PubMed** (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\_uids=22041254)  
**Google Scholar** (http://scholar.google.com/scholar\_lookup?title=Physician%20Global%20Assessment%20%28PGA%29%20and%20Psoriasis%20Area%20and%20Severity%20Index%20%28PASI%29%3A%20why%20do%20both%3F%20A%20systematic%20analysis%20of%20randomized%20controlled%20trials%20of%20biologic%20agents%20for%20moderate%20to%20severe%20plaque%20psoriasis&author=A.%20Robinson&author=M.%20Kardos&author=AB.%20Kimball&journal=J%20Am%20Acad%20Dermatol&volume=66&issue=3&pages=369-375&publication\_year=2012&doi=10.1016%2Fj.jaad.2011.01.022)
35. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. *J Investig Dermatol.* 2010 Apr 1;130(4):933–43.  
**CrossRef** (https://doi.org/10.1038/jid.2009.391)  
**Google Scholar** (http://scholar.google.com/scholar\_lookup?title=How%20good%20are%20clinical%20severity%20and%20outcome%20measures%20for%20psoriasis%3F%3A%20quantitative%20evaluation%20in%20a%20systematic%20review&author=PI.%20Spuls&author=LL.%20Lecluse&author=ML.%20Poulsen&author=JD.%20Bos&author=RS.%20Stern&author=T.%20Nijsten&journal=J%20Investig%20Dermatol.&volume=130&issue=4&pages=933-943&publication\_year=2010)

## Copyright information

© Springer Nature Switzerland AG 2020

## About this article

Cite this article as:

Perez-Chada, L.M., Salame, N.F., Ford, A.R. et al. Am J Clin Dermatol (2020). <https://doi.org/10.1007/s40257-019-00496-w>

- First Online 16 January 2020
- DOI <https://doi.org/10.1007/s40257-019-00496-w>
- Publisher Name Springer International Publishing
- Print ISSN 1175-0561
- Online ISSN 1179-1888

- [About this journal](#)
- [Reprints and Permissions](#)



Published in cooperation with

[Adis](#)

## Personalised recommendations

### SPRINGER NATURE

© 2019 Springer Nature Switzerland AG. Part of [Springer Nature](#).

Not logged in Not affiliated 45.25.206.87